MarioBerger WuppertalGermany

• Advancing the next wave of therapies in chronic kidney disease
• Effects of finerenone on biomarkers: Mechanistic insights from proteomic analyses in clinical trials
  MarioBerger Speaker Germany
• Future Directions in CRM Care: Advancing Research and Therapeutic Innovation
  AntonioGarreta Rufas Speaker Germany
• Innovative strategies for clinical trial design in IgAN
• Improving outcomes in complement-mediated kidney diseases
  Marianne Silkjær Nielsen Speaker Switzerland
• Advancing Mechanistic Trials through Industry–Academia Collaboration: Insights from the REMODEL Trial
  ManuelMayrdorfer Speaker Denmark
• Why? When? How? How to maximize patient outcomes from the start of dialysis
  PeterRutherford Speaker Switzerland

• EFFECT OF A 12-WEEK INTRADIALYTIC CYCLING INTERVENTION ON HEMODIALYSIS-INDUCED MYOCARDIAL STUNNING: A MULTI-CENTRE RANDOMIZED CONTROLLED TRIAL (TICKERS_HD)
  ClaraBohm Speaker Canada
• EFFECT OF FINERENONE ON CIRCULATING BIOMARKERS: A CONFIDENCE ANALYSIS
  MarioBerger Speaker Germany
• EFFECT OF SIMULTANEOUS INITIATION OF FINERENONE AND EMPAGLIFLOZIN ON URINARY ALBUMIN-TO-CREATININE RATIO BY AGE AND SEX IN THE CONFIDENCE TRIAL
  RajivAgarwal Speaker United States
• A CONTROLLED, RANDOMIZED CLINICAL TRIAL OF PERSONALIZED TWO-PHASE REGIONAL CITRATE ANTICOAGULATION IN PROLONGED INTERMITTENT KIDNEY REPLACEMENT THERAPY
  QiZhang Speaker China
• LOWERING-HYPERURICEMIA TREATMENT ON CARDIOVASCULAR OUTCOMES IN PERITONEAL DIALYSIS PATIENTS: A PROSPECTIVE, MULTICENTER, DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL
  Naya Huang Speaker China